Back to Results
First PageMeta Content
Benign prostatic hyperplasia / Tadalafil / Prostate / CGMP-specific phosphodiesterase type 5 / Lower urinary tract symptoms / Alpha-1 blocker / Erectile dysfunction / PDE5 inhibitor / Urination / Medicine / Anatomy / Lactams


Special Feature Nippon Shinyaku Launches Zalutia®, a Breakthrough New Drug for Urinary Disorders Caused by Benign Prostatic Hypertrophy Benign prostatic hypertrophy, or BPH, negatively affects a patient’s quality of
Add to Reading List

Document Date: 2014-11-10 02:30:14

Open Document

File Size: 403,79 KB

Share Result on Facebook

Company

Nippon Shinyaku / /

Continent

Europe / /

Country

Japan / /

Event

Product Release / /

IndustryTerm

hypertension treatment / Tadalafil Erectile dysfunction treatment / tadalafil products / an erectile dysfunction treatment / BPH treatment / /

MedicalCondition

hypertension / BPH / urinary disorders / pulmonary arterial hypertension / erectile dysfunction / inflammation / urological disorders / Tadalafil Erectile dysfunction treatment Pulmonary / prostatic hypertrophy / /

MedicalTreatment

surgery / /

Organization

Statistics and Information Department / Minister's Secretariat / Ministry of Health / /

Product

Cialis / Zalutia / Ensuring Proper Drug / /

Technology

alpha / /

URL

http /

SocialTag